Edesa Biotech, Inc. (EDSA) stock
EDSANasdaqPharmaceutical PreparationsFiscal year ends September 30
$1.96+0.07 (+3.70%)
Close on Nov 17, 2026Market cap $18.90MP/E –Yield –
Earnings
Edesa Biotech's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Dec 11, 2026
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.60
-$0.25 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Edesa Biotech's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Sep 30, 2026 | Dec 11, 2026Expected | – | – | – | – |
| Q3 FY2026ended Jun 30, 2026 | Aug 13, 2026after the close | – | – | -$0.60 | Release |
| Q2 FY2026ended Mar 31, 2026 | May 14, 2026after the close | – | – | -$0.49 | Release |
| Q1 FY2026ended Dec 31, 2025 | Feb 13, 2026after the close | – | – | -$0.28 | Release |
| Q4 FY2025ended Sep 30, 2025 | Dec 12, 2025after the close | – | – | – | Release |
| Q3 FY2025ended Jun 30, 2025 | Aug 8, 2025after the close | – | – | -$0.25 | Release |
| Q2 FY2025ended Mar 31, 2025 | May 14, 2025after the close | – | – | -$0.30 | Release |
| Q1 FY2025ended Dec 31, 2024 | Feb 14, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Sep 30, 2024 | Dec 13, 2024after the close | – | – | – | Release |
| Q3 FY2024ended Jun 30, 2024 | Aug 9, 2024after the close | – | – | -$0.52 | Release |
| Q2 FY2024ended Mar 31, 2024 | May 10, 2024after the close | – | – | -$0.58 | Release |
| Q1 FY2024ended Dec 31, 2023 | Feb 9, 2024after the close | – | – | -$0.54 | Release |
| Q4 FY2023ended Sep 30, 2023 | Dec 15, 2023after the close | – | – | – | Release |
| Q3 FY2023ended Jun 30, 2023 | Aug 9, 2023after the close | – | – | -$0.10 | Release |
| Q2 FY2023ended Mar 31, 2023 | May 11, 2023after the close | – | – | -$0.12 | Release |
| Q1 FY2023ended Dec 31, 2022 | Feb 10, 2023before the open | – | – | -$0.13 | Release |
| Q4 FY2022ended Sep 30, 2022 | Dec 16, 2022before the open | – | – | – | Release |
| Q3 FY2022ended Jun 30, 2022 | Aug 12, 2022after the close | – | – | -$0.37 | Release |
| Q2 FY2022ended Mar 31, 2022 | May 13, 2022before the open | – | – | -$0.33 | Release |
| Q1 FY2022ended Dec 31, 2021 | Feb 14, 2022before the open | – | – | -$0.33 | Release |
| Q4 FY2021ended Sep 30, 2021 | Dec 28, 2021after the close | – | – | – | Release |
| Q3 FY2021ended Jun 30, 2021 | Aug 13, 2021before the open | – | – | – | Filing |
| Q2 FY2021ended Mar 31, 2021 | May 14, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Dec 31, 2020 | Feb 16, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Sep 30, 2020 | Dec 7, 2020before the open | – | – | – | Filing |
| Q3 FY2020ended Jun 30, 2020 | Aug 12, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Edesa Biotech has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Edesa Biotech puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Edesa Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- News
- Results
- News
- Results
- Results
See a number that looks wrong?